Affinage

CCL17

C-C motif chemokine 17 · UniProt Q92583

Length
94 aa
Mass
10.5 kDa
Annotated
2026-06-09
100 papers in source corpus 44 papers cited in narrative 44 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CCL17 (TARC) is a CC chemokine that signals through the receptor CCR4 to direct T cell trafficking and shape the balance between effector and regulatory immunity across allergic, inflammatory, fibrotic, malignant, and neural contexts (PMID:29103909, PMID:21633167). Engagement of CCR4 — confirmed by receptor-blocking antibodies, antagonists, and CCR4 internalization upon ligand binding — drives chemotaxis and downstream signaling that varies by target cell: RhoA/Rho-kinase activation sustaining cancer cell migration (with geranylgeranylation and miR-155-5p stabilization of RhoA mRNA as upstream regulators) (PMID:23649168, PMID:24582560, PMID:28146427), ERK1/2-MMP13 in bladder cancer (PMID:30230587), TGF-β/Smad in fibroblast activation and fibrosis (PMID:36870575), and PI3K/AKT/Foxo1, ERK/Nrf2/CD163, and mTOR signaling in microglia after brain injury (PMID:33648537, PMID:32783091, PMID:35882433). CCL17 distinguishes itself from the co-ligand CCL22 through biased CCR4 signaling, activating Gq but not β-arrestin, allowing it to competitively restrain CCL22-driven regulatory T cell recruitment (PMID:35113652). Functionally, CCL17 produced by dendritic cells and macrophages limits Foxp3+ Treg maintenance and expansion and promotes Th2/Th1/Th17 responses, thereby exacerbating atherosclerosis, intestinal inflammation, arthritis, cardiac remodeling, and allergic airway disease (PMID:21633167, PMID:22057112, PMID:24661094, PMID:35687056). Its transcription is induced cooperatively by IL-4 and GM-CSF via a STAT6→JMJD3→IRF4 axis and by TNF-α/IFN-γ through NF-κB and p38 MAPK, with STAT5/NF-κB mediating GM-CSF induction and EZH2-deposited H3K27me3 epigenetically repressing the promoter (PMID:29871928, PMID:16117790, PMID:35113652, PMID:34449935). Beyond chemotaxis, CCL17 also induces platelet aggregation (PMID:11248289) and neuropeptide (CGRP) release from airway epithelium (PMID:23731651), and modulates hippocampal synaptic transmission (PMID:30277599).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2001 Medium

    Established that CCL17 acts through CCR4 as a functional ligand, here on platelets, defining the receptor that mediates its downstream biology.

    Evidence Flow cytometry for CCR4 on platelets, calcium flux, aggregation assays with anti-CCR4 blocking antibody

    PMID:11248289

    Open questions at the time
    • Physiological relevance of platelet CCR4 signaling unclear
    • Downstream signaling pathway not delineated
  2. 2003 Medium

    Localized CCL17 production to skin Langerhans cells, keratinocytes, and endothelium in atopic disease and defined cytokine control (TNF-α/IL-4 upregulate, IFN-γ/TGF-β1 downregulate), framing CCL17 as a cytokine-regulated mediator of cutaneous Th2 inflammation.

    Evidence In situ RT-PCR, ELISA/RT-PCR in HaCaT and murine Langerhans cells, adenoviral Smad gene transfer

    PMID:12598706 PMID:12615362 PMID:12615364 PMID:12967648

    Open questions at the time
    • HaCaT vs primary keratinocyte discrepancy in CCL17 production
    • Transcription factor mediators not yet identified
  3. 2004 Medium

    Demonstrated in vivo that CCL17 recruits CD4+ Th2 cells, induces IL-4 and an autocrine production loop, and is co-expressed with adhesion molecules in noninflamed skin, establishing its role in both constitutive immunosurveillance and inducible Th2 inflammation.

    Evidence Intradermal injection in mice with histology/RT-PCR, confocal multicolor immunofluorescence of human skin

    PMID:14734737 PMID:15086343

    Open questions at the time
    • Mechanism of autocrine loop not defined
    • CCR4 signaling consequences in recruited cells not dissected
  4. 2006 High

    Defined the transcriptional logic of CCL17 induction, showing IL-4 acts through multiple STAT6 binding sites in the promoter in both human T cells and murine macrophages, and that pathogen/allergen signals converge on NF-κB.

    Evidence EMSA, ChIP, site-directed mutagenesis, reporter assays in T cells and macrophages; kinase inhibitors and gel-shift in bronchial epithelium

    PMID:16117790 PMID:16810739 PMID:17023689 PMID:17134490

    Open questions at the time
    • Cooperative integration of STAT6 and NF-κB inputs not fully resolved
    • Cell-type specificity of promoter usage unclear
  5. 2007 Medium

    Showed that viral (NF-κB) and Th2 cytokine (STAT6) signals synergize on the CCL17 promoter, mechanistically linking respiratory virus infection to amplified Th2 chemokine output.

    Evidence RSV plus cytokine stimulation in lung epithelial cells, in vivo mouse priming model, ELISA

    PMID:17641031

    Open questions at the time
    • Direct demonstration of combinatorial promoter occupancy not shown
  6. 2008 Medium

    Identified CCL17 as a non-chemotactic signaling ligand that reprograms β2-adrenergic receptor signaling in T cells, and demonstrated that STAT6-dependent CCL17 output is targetable by HDAC inhibition in lymphoma.

    Evidence Phosphorylation/Co-IP/reporter assays in primary T cells; vorinostat treatment with Western blot/RT-PCR/ELISA in Hodgkin lymphoma cells

    PMID:15749741 PMID:18541724

    Open questions at the time
    • Physiological role of β2-AR crosstalk in vivo unclear
    • Whether CCR4 mediates the β2-AR effect not confirmed
  7. 2011 High

    Established the central immunoregulatory function: dendritic-cell-derived CCL17 restrains Foxp3+ Treg expansion and promotes effector responses, with genetic and antibody evidence linking it causally to atherosclerosis and colitis.

    Evidence Ccl17E/E knockout mice, blocking antibody, T cell transfer epistasis, flow cytometry in atherosclerosis and DSS colitis models

    PMID:21633167 PMID:22057112

    Open questions at the time
    • Molecular basis of how CCL17 biases Treg vs effector recruitment not yet defined (resolved later)
    • Autocrine DC signaling receptor/pathway not fully mapped
  8. 2013 Medium

    Showed CCL17 drives tumor cell migration via a CCR4-RhoA/Rho-kinase axis and induces neuropeptide (CGRP) release from airway epithelium, broadening its functions beyond leukocyte chemotaxis.

    Evidence Transwell migration, G-LISA RhoA activation, CCR4 antibody/antagonist in colon cancer; anti-CCR4 blockade and CCR4 internalization in primary airway cells

    PMID:23649168 PMID:23731651

    Open questions at the time
    • Generality of RhoA axis across tumor types not yet established
    • Link between CGRP induction and disease unclear
  9. 2014 High

    Extended CCL17-CCR4 migratory signaling to trophoblast invasion and established the metabolic/regulatory inputs to its RhoA axis (HMG-CoA reductase/geranylgeranylation) and its in vivo requirement in NOD1-driven Th2 asthma.

    Evidence Migration/invasion assays with MMP/integrin Western blots; statin and GGPP rescue with G-LISA; adoptive transfer of CCL17-deficient DCs in asthma model

    PMID:24401476 PMID:24582560 PMID:24661094

    Open questions at the time
    • Whether trophoblast and tumor RhoA pathways are mechanistically identical not tested
    • DC-intrinsic CCL17 signaling receptor not fully resolved
  10. 2018 High

    Resolved the full transcriptional cascade for IL-4/GM-CSF induction (STAT6→JMJD3→IRF4) and placed CCL17 downstream of GM-CSF in a TNF→GM-CSF→JMJD3→IRF4→CCL17 pain pathway, establishing CCL17 as a required effector in inflammatory and arthritic pain.

    Evidence siRNA, ChIP, gain/loss-of-function in primary human/murine myeloid cells; Irf4-/- and Ccl17E/E mice with temporal antibody blockade in arthritis/pain models

    PMID:29563337 PMID:29622035 PMID:29871928

    Open questions at the time
    • How CCL17 produces pain at the cellular level not fully defined (partly addressed in 2020)
    • Direct STAT6/IRF4 co-occupancy dynamics not resolved
  11. 2018 High

    Defined a novel CNS role: CCL17 is produced by hippocampal CA1 neurons, regulates microglial density and morphology, and modulates synaptic transmission, with distinct TNF (vs GM-CSF for CCL22) upstream control.

    Evidence Reporter mice, LPS challenge, patch-clamp electrophysiology of Schaffer collaterals, morphometry, TNF/GM-CSF blockade

    PMID:30277599

    Open questions at the time
    • Receptor and signaling pathway mediating neuronal CCL17 effects on synapses not identified
    • Behavioral consequences unclear
  12. 2018 Medium

    Linked metabolic enzymes (ALOX15B/SREBP-2) to CCL17 production in IL-4 macrophages and extended the tumor RhoA axis to bladder cancer (CCR4-ERK1/2-MMP13), refining the upstream and downstream signaling network.

    Evidence siRNA of ALOX15B with SREBP-2 ChIP and T cell migration; CCR4 siRNA with ERK/MMP13 Western blots and invasion assays

    PMID:30197642 PMID:30230587

    Open questions at the time
    • Whether ERK and RhoA axes operate in parallel across tumors unclear
    • Lipid-metabolic control of CCL17 not validated in vivo
  13. 2020 High

    Mapped the cellular and downstream-mediator requirements for CCL17 in pain (CCR4+ radiation-resistant cells; NGF/CGRP/substance P required) and identified beneficial CCR4-ERK-Nrf2-CD163 signaling in microglia that promotes hematoma resolution after brain hemorrhage.

    Evidence Radiation chimeras, reporter mice, mediator-blocking antibodies in pain; rCCL17 with CRISPR CD163 knockout and pharmacological inhibitors in ICH model

    PMID:32461237 PMID:32783091

    Open questions at the time
    • Reconciling pathogenic (pain/inflammation) vs protective (CNS injury) CCL17 roles unresolved
    • Cell type expressing CCR4 in pain not molecularly identified
  14. 2021 Medium

    Established multiple context-specific CCR4 effector pathways — PI3K/AKT/Foxo1 neuroprotection and mTORC1 tumor invasion — and demonstrated EZH2/H3K27me3 epigenetic repression of the CCL17 promoter as a regulatory and therapeutic node.

    Evidence rCCL17 with C021/AKT inhibitors in ICH; pathway inhibitors in pituitary adenoma TAM model; tazemetostat with H3K27me3 ChIP and T cell migration in lymphoma

    PMID:33648537 PMID:33664865 PMID:34449935

    Open questions at the time
    • How a single receptor selects among PI3K/AKT, mTOR, ERK, and RhoA outputs unclear
    • In vivo relevance of EZH2 repression to disease not established
  15. 2022 High

    Provided the biochemical basis for CCL17's selective immunoregulation: biased CCR4 signaling (Gq but not β-arrestin) lets CCL17 competitively block CCL22-driven Treg recruitment, with GM-CSF→STAT5/NF-κB driving its expression, accounting for its Treg-restraining and disease-promoting roles in cardiac injury, hypertrophy, and CNS injury.

    Evidence Ccl17 knockout mice, RNA-seq, Gq vs ARRB signaling dissection and competitive inhibition assays, Treg trafficking; neutralizing antibody in Ang II model; in vitro kinase assay and Rictor knockdown in SAH microglia

    PMID:35113652 PMID:35687056 PMID:35882433

    Open questions at the time
    • Structural basis of CCL17 vs CCL22 biased agonism at CCR4 not defined
    • Whether biased signaling explains CCL17 actions in all tissues untested
  16. 2023 Medium

    Identified the fibrogenic mechanism: CCL17 acts on CCR4 on fibroblasts to activate TGF-β/Smad signaling and collagen production, unifying its roles in peritoneal, renal, and pulmonary fibrosis.

    Evidence CCR4 siRNA/antagonist, anti-CCL17 antibody, bleomycin mouse model, TGF-β/Smad Western blots

    PMID:36870575

    Open questions at the time
    • Direct fibroblast CCR4 signaling linkage to Smad activation not fully isolated from macrophage contributions
    • Cross-organ generality of TGF-β/Smad mechanism not formally tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single receptor (CCR4) selects among the divergent downstream programs CCL17 elicits — RhoA, ERK, PI3K/AKT/Foxo1, mTORC1/2, and TGF-β/Smad — and what structural features underlie CCL17 vs CCL22 biased agonism remains unresolved.
  • No structural model of CCL17-CCR4 biased signaling
  • Determinants of cell-type-specific effector pathway selection unknown
  • Mechanistic reconciliation of pathogenic vs protective CCL17 roles unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 3 GO:0060089 molecular transducer activity 3
Localization
GO:0005576 extracellular region 3
Pathway
R-HSA-1500931 Cell-Cell communication 3 R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3
Partners
CCR4

Evidence

Reading pass · 44 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 CCL17 (TARC) binds CCR4 and induces concentration-dependent platelet aggregation and calcium flux; CCR4 expression on platelets was confirmed by flow cytometry, and anti-CCR4 monoclonal antibody inhibited CCL17-induced aggregation. Full platelet aggregation required cyclooxygenase metabolites (blocked by aspirin) and plasma components. Flow cytometry (CCR4 on platelets), calcium flux assay, platelet aggregation assay, antibody inhibition Thrombosis research Medium 11248289
2003 CCL17 (TARC) is expressed by Langerhans cells and keratinocytes in atopic dermatitis lesions; mRNA localization by in situ RT-PCR showed expression in epidermal keratinocytes, dermal endothelial cells, and infiltrating cells, with CCR4 mRNA in endothelial and infiltrating cells. In situ RT-PCR The Journal of dermatology Low 12598706
2003 TGF-β1 inhibits IFN-γ/TNF-α-induced CCL17 (TARC) production in HaCaT keratinocytes via Smad2/3 signaling; overexpression of Smad7 (inhibitory Smad) reversed TGF-β1 suppression, while overexpression of Smad2 or Smad3 alone was sufficient to inhibit CCL17 production. Adenoviral gene transfer of Smad constructs, RT-PCR, ELISA Journal of dermatological science Medium 12615364
2003 Normal human epidermal keratinocytes (NHEK) do not produce detectable CCL17 protein in vitro even after cytokine stimulation; CCL17 production observed in HaCaT cells is a cell-line-specific phenomenon. ELISA, RT-PCR Journal of dermatological science Medium 12615362
2003 Murine Langerhans cells produce CCL17 (TARC) that is upregulated by TNF-α and IL-4 and downregulated by IFN-γ in a dose-dependent manner. RT-PCR (mRNA), ELISA (protein) on cultured murine Langerhans cells Cytokine Medium 12967648
2004 CCL17 (TARC) and ICAM-1 are constitutively co-expressed with E-selectin in dermal microvascular endothelium of noninflamed human skin, as demonstrated by confocal multicolor immunofluorescence, providing a basis for constitutive cutaneous T cell immunosurveillance via CCR4. Confocal multicolor immunofluorescence, immunohistochemistry Journal of immunology Medium 14734737
2004 Intradermal injection of TARC/CCL17 in BALB/c mice induced CD4+ lymphocyte infiltration in a dose-dependent manner, induced IL-4 mRNA (but not IFN-γ mRNA) expression, and induced its own production (autocrine loop) in keratinocytes along with CCL27 mRNA, demonstrating a Th2-dominated inflammatory reaction. In vivo intradermal injection, histology, RT-PCR Experimental dermatology Medium 15086343
2005 TNF-α and IFN-γ synergistically induce CCL17 production from HaCaT keratinocytes via NF-κB and p38 MAPK pathways; inhibitors of NF-κB and p38 blocked this production, and EGFR tyrosine kinase inhibition paradoxically enhanced CCL17 production. Roxithromycin suppressed CCL17 via partial inhibition of p38 and NF-κB, independently of IκBα degradation. Pharmacological inhibitors, NF-κB-driven luciferase reporter assay, ELISA, Western blot The Journal of investigative dermatology Medium 16117790
2005 CCL17 (TARC) impairs β2-adrenergic receptor (β2-AR) function in human peripheral blood T lymphocytes by activating Src kinases, leading to GRK2 membrane translocation, Src-dependent serine phosphorylation of β2-AR, β-arrestin association, and a switch from cAMP/CREB signaling to MAPK pathway activation. Phosphorylation assays (Western blot), co-immunoprecipitation (GRK2/β-arrestin association), cAMP/CREB reporter, MAPK activation assay in primary human T cells American journal of physiology. Lung cellular and molecular physiology Medium 15749741
2006 IL-4 induces CCL17 (TARC/CCL17) expression in human T cells via two STAT6 binding motifs in the CCL17 promoter; EMSA and chromatin immunoprecipitation confirmed STAT6 binding to both sites; site-directed mutagenesis showed both sites are required for full IL-4-induced promoter activity. EMSA, chromatin immunoprecipitation, reporter gene assay, site-directed mutagenesis European journal of immunology High 16810739
2006 IL-4 induction of mTARC/CCL17 in murine macrophages requires STAT6 and is mediated by cooperative interactions among multiple STAT6 binding sites in the mTARC promoter; in vitro binding assays and transient transfection identified five functional STAT6 sites, with the two most proximal sites (conserved with human) being most critical. In vitro STAT6 binding assays, transient transfection with isolated promoter fragments, site-directed mutagenesis, primary macrophage culture BMC molecular biology High 17134490
2006 House dust mite allergen (Der p), IL-4, and TGF-β cooperatively induce CCL17 (TARC) expression in bronchial epithelial cells via ADAM-mediated EGFR transactivation, MAPK signaling, and NF-κB activation; supernatants induced TARC-dependent T cell trafficking. Specific kinase inhibitors, immunodetection, gel-shift assays, chemotaxis assay, primary bronchial epithelial cells American journal of respiratory cell and molecular biology Medium 17023689
2007 RSV infection synergizes with IL-4/IL-13 to induce optimal CCL17 (TARC) production in lung epithelial cells; this reflects differential induction of NF-κB (by RSV) and STAT6 (by Th2 cytokines), both of which are present in the TARC promoter. In vitro cell culture with RSV and cytokines, in vivo mouse model with vaccinia priming, TARC ELISA Journal of immunology Medium 17641031
2008 HDAC inhibitor vorinostat inhibits STAT6 phosphorylation and decreases its mRNA levels in Hodgkin lymphoma cells, causing reduced CCL17 (TARC) expression and secretion; vorinostat also inhibited TSLP-activated dendritic cell CCL17 secretion. Western blot (STAT6 phosphorylation), RT-PCR, ELISA, dose-response analysis Blood Medium 18541724
2008 EBV latent membrane protein 1 (LMP1) drives CCL17 and CCL22 production in B cells through NF-κB activation; LMP1-expressing large tumor cells in ALPD selectively expressed CCL17 and CCL22, attracting CCR4+ T cells and Foxp3+ regulatory T cells. Immunohistochemistry, previously reported mechanistic link via NF-κB in EBV-immortalized B cells Cancer science Low 18271928
2009 The adenylyl cyclase-cAMP system suppresses IFN-γ/TNF-α-induced CCL17 (TARC) and CCL22 production in HaCaT keratinocytes by inhibiting NF-κB activation through the p38 MAPK pathway; forskolin and dibutyryl-cAMP both suppressed p38 phosphorylation and NF-κB-driven responses. Pharmacological activators of adenylyl cyclase, p38 inhibitor, NF-κB inhibitor, ELISA, Western blot Molecular immunology Medium 19371952
2010 CCL17 suppresses sulforaphane-inducible heme oxygenase-1 (HO-1)-mediated inhibition of CCL17/CCL22 in keratinocytes: HO-1 siRNA abolished suppression and carbon monoxide (but not other HO-1 products) replicated the effect, demonstrating that HO-1-derived CO mediates the CCL17-suppressive pathway. siRNA knockdown of HO-1, exogenous CO treatment, Western blot, ELISA Archives of pharmacal research Medium 21116791
2011 CCL17 deficiency (Ccl17E/E mice) leads to expansion of Foxp3+ regulatory T cells, reduces atherosclerosis in atherosclerosis-prone mice, and this protection is dependent on Tregs; CCL17 expressed by DCs limits Treg maintenance and expansion. A blocking antibody specific for CCL17 expanded Tregs and reduced atheroprogression. Knockout mouse model, blocking antibody treatment, T cell transfer, flow cytometry The Journal of clinical investigation High 21633167
2011 CCL17 promotes intestinal inflammation and counteracts regulatory T cell-mediated colitis protection: CCL17 has an autocrine effect on DCs promoting IL-12 and IL-23 secretion (TLR-induced), Th1/Th17 differentiation, and reduced Foxp3+ Treg induction. CCR4 expression by recipients (not transferred T cells) was required for colitis induction. DSS colitis and T cell transfer models in Ccl17E/E mice, in vitro DC/T cell differentiation assays, cytokine profiling Gastroenterology High 22057112
2013 CCL17 (TARC) induces CGRP synthesis and secretion in human airway epithelial cells via CCR4; CCL17-induced CGRP release was blocked by an anti-CCR4 antibody and CCR4 was internalized after CCL17 ligation. CCL17 induced a greater CGRP release than IL-13, CCL22, or TNF-α/GM-CSF/IL-1 mixture. RT-PCR, quantitative immunofluorescence, enzyme immunoassay, anti-CCR4 blocking antibody, CCR4 internalization by flow cytometry, primary human airway cells The Journal of allergy and clinical immunology Medium 23731651
2013 CCL17 (TARC) induces migration of colon cancer cells (HT-29, AZ-97) via CCR4, with downstream activation of RhoA and Rho-kinase; CCR4 antagonist or anti-CCR4 antibody inhibited migration; Rho-kinase inhibitor Y-27632 and isoprenylation inhibitor GGTI-2133 abolished CCL17-induced chemotaxis. Transwell migration assay, ELISA and G-LISA for RhoA activation, CCR4 antibody/antagonist inhibition, RT-PCR International journal of colorectal disease Medium 23649168
2014 CCL17 induces trophoblast migration and invasion via CCR4, upregulating MMP-2, MMP-13, integrin α5, and integrin β1 while downregulating TIMP-1; CCL17 and CCR4 were co-expressed at the fetomaternal interface (CCL17 in decidua/trophoblasts, CCR4 on invading interstitial extravillous trophoblasts). Immunohistochemistry, transwell migration and invasion assays, Western blot Reproductive sciences Medium 24401476
2014 HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation; simvastatin reduced CCL17-induced RhoA activation and migration, reversed by mevalonate and geranylgeranyl pyrophosphate (GGPP). G-LISA (active RhoA), transwell migration assay, pharmacological rescue with mevalonate and GGPP Biochemical and biophysical research communications Medium 24582560
2014 CCL17 production by synovial macrophages in osteoarthritis requires IRF4 expression, which is downstream of GM-CSF, with Jmjd3 (demethylase) as an intermediate; genetic deletion of IRF4, CCL17, or CCR4 reduced both pain and cartilage destruction/osteophyte formation in collagenase-induced OA (CiOA) model. Gene-deficient mice (Irf4-/-, Ccl17E/E, Ccr4-/-), therapeutic antibody neutralization, cell sorting with qPCR Arthritis research & therapy High 29622035
2014 NOD1 ligation of dendritic cells directly induces CCL17 (and CCL22) production, driving Th2 responses; adoptive transfer of NOD1-conditioned wild-type DCs (but not CCL17-deficient DCs) exacerbated experimental asthma, demonstrating that DC-derived CCL17 mediates NOD1-driven Th2 amplification in vivo. In vitro DC culture with NOD1 agonist, adoptive transfer of DCs from wild-type vs. CCL17-deficient mice, mouse asthma model American journal of respiratory and critical care medicine High 24661094
2016 CCL17 stimulates submesothelial fibroblast migration and collagen production (CCL17-CCR4 axis); antibody blockade of CCL17 reduced macrophages, myofibroblasts, and fibrosis and improved peritoneal function in a mouse model; inflammatory macrophages switch to CCL17/CCL22/arginase-1-expressing phenotype after injury. In vitro fibroblast culture with CCL17, diphtheria toxin macrophage ablation, anti-CCL17 antibody treatment, fate-mapping reporter mice, chimeric mice The Journal of pathology High 31579932
2017 RNA aptamers against CCL17 inhibit CCR4-dependent T cell chemotaxis in vitro and significantly prevent ear swelling and T cell infiltration in a murine contact hypersensitivity model in vivo, validating CCL17-CCR4 as a chemotactic axis. Transwell chemotaxis assay, in vivo contact hypersensitivity model with systemic aptamer administration Molecular therapy Medium 29103909
2017 miR-155-5p positively regulates CCL17-induced colon cancer cell migration by targeting the 3'-UTR AU-rich elements of RhoA mRNA, thereby sustaining RhoA mRNA levels; knockdown of miR-155-5p decreased CCL17-provoked RhoA activation and cell chemotaxis; validated by RNA immunoprecipitation and target site blocker. miRNA knockdown, RNA immunoprecipitation, target site blocker, RhoA activation assay, chemotaxis assay Oncotarget Medium 28146427
2018 CCL17 is expressed in hippocampal CA1 neurons in mice; LPS-induced Ccl17 upregulation in the hippocampus depends on local TNF signaling (while CCL22 upregulation requires GM-CSF). CCL17 deficiency reduces microglia density and alters microglia morphology; electrophysiology showed CCL17 downmodulates basal synaptic transmission at CA3-CA1 Schaffer collaterals. Fluorescence reporter mouse model, LPS challenge, electrophysiology (patch-clamp of Schaffer collaterals), computer-assisted morphological analysis, TNF/GM-CSF blocking Glia High 30277599
2018 IL-4 induces CCL17 production in human monocytes and murine macrophages via IRF4 in a STAT6-dependent manner; IL-4 upregulates IRF4 at the epigenetic level by increasing JMJD3 demethylase expression and activity. ChIP showed increased STAT6 association at promoters of CCL17, IRF4, and JMJD3 genes. STAT6 silencing decreased CCL17, JMJD3, and IRF4. siRNA gene silencing (STAT6, IRF4, JMJD3), ChIP assay, ELISA, Western blot, primary human monocytes and murine macrophages The Journal of biological chemistry High 29871928
2018 TNF drives inflammatory pain and arthritic pain initiation via a GM-CSF→JMJD3→IRF4→CCL17 pathway; once arthritis is established, blockade of GM-CSF or CCL17 (but not TNF) still ameliorates disease, showing CCL17 acts downstream of both TNF and GM-CSF and is required throughout disease course. In vivo zymosan/arthritis models, antibody blockade of TNF/GM-CSF/CCL17, Irf4-/- and Ccl17E/E mice JCI insight High 29563337
2018 CCL17 promotes bladder cancer cell migration and invasion via CCR4-ERK1/2-MMP13 axis; CCR4 knockdown attenuated invasive capability; exogenous CCL17 induced CCR4 expression, ERK1/2 phosphorylation, and MMP13 activation. siRNA knockdown of CCR4, Western blot (ERK1/2, MMP13), migration/invasion assays Journal of cellular biochemistry Medium 30230587
2018 15-Lipoxygenase isoform ALOX15B (and to lesser extent ALOX15) regulates CCL17 production in IL-4-stimulated human macrophages through an SREBP-2-dependent mechanism; silencing ALOX15B reduced SREBP-2 processing, cellular cholesterol intermediates, and CCL17 production, with functional consequence on T cell migration. siRNA knockdown of ALOX15/ALOX15B, SREBP-2 ChIP, sterol measurement, T cell migration assay Frontiers in immunology Medium 30197642
2019 CD248 on fibroblasts interacts with macrophage galectin-3, which then induces CCL17 expression in macrophages; galectin-3-deficient macrophages show decreased CCL17 in fibrotic kidneys. CCL17 produced by macrophages then stimulates fibroblast collagen production. CD248 knockout reduces CCL17/CCL22 in macrophages and attenuates fibrosis. Co-IP/interaction studies (CD248-galectin-3), Cd248 knockout mice, galectin-3-deficient macrophages, parabiosis, reporter mice Scientific reports Medium 33033277
2020 Recombinant CCL17 (rCCL17) activates CCR4/ERK/Nrf2/CD163 signaling in microglia to promote hematoma resolution after intracerebral hemorrhage; CCR4 co-localizes with microglia; rCCL17 increased ERK1/2 phosphorylation, Nrf2, and CD163 expression and reduced hematoma volume/brain edema. Effects were abolished by CCR4 inhibitor C021, Nrf2 inhibitor ML385, and CD163 CRISPR knockout. In vivo ICH mouse model, recombinant CCL17 intranasal delivery, pharmacological inhibitors (C021, ML385), CRISPR knockout of CD163, Western blot, immunofluorescence Neurotherapeutics Medium 32783091
2020 CCL17 in inflammatory pain and arthritis acts on CCR4+ non-bone-marrow-derived (radiation-resistant) cells; nerve growth factor (NGF), CGRP, and substance P are all required downstream of CCL17 for inflammatory pain development; CCL17 expression in inflammation models is predominantly in macrophage lineage populations and is GM-CSF-dependent. Radiation chimera approach, cell depletion, CCL17 reporter mice, gene-deficient mice, blocking antibodies to NGF/CGRP/substance P Journal of immunology High 32461237
2021 Lactate from pituitary adenoma cells induces M2 polarization of tumor-associated macrophages via mTORC2 and ERK signaling pathways; activated TAMs then secrete CCL17 to promote PA invasion via the CCL17/CCR4/mTORC1 axis; CCR4 signaling inhibition reduced invasion in vitro and in vivo. siRNA knockdown, specific pathway inhibitors (mTORC2, ERK, mTORC1), in vitro invasion assays, in vivo mouse model Theranostics Medium 33664865
2021 Recombinant CCL17-dependent CCR4 activation alleviates neuroinflammation and neuronal apoptosis after intracerebral hemorrhage via the PI3K/AKT/Foxo1 signaling pathway; rCCL17 increased CCR4, PI3K, phospho-AKT, and Bcl-2, while decreasing Foxo1, IL-1β, TNF-α, and Bax. Effects were reversed by CCR4 inhibitor C021 or AKT inhibitor GDC0068. In vivo ICH mouse model, intranasal rCCL17, pharmacological inhibitors (C021, GDC0068), Western blot, immunofluorescence, TUNEL staining Journal of neuroinflammation Medium 33648537
2021 EZH2 inhibitor tazemetostat upregulates CCL17 expression in B-cell lymphoma cells by inducing H3K27 demethylation at the CCL17 promoter; ChIP showed H3K27me3 enrichment at the CCL17 promoter, and tazemetostat treatment increased H3K27 demethylation and activated CCL17 gene transcription. CCL17 protein produced enhanced T cell recruitment in vitro. ChIP for H3K27me3, Western blot, ELISA, transwell T cell migration assay, gene set enrichment analysis Cancer science Medium 34449935
2021 Rhinovirus-induced CCL17 expression in airway epithelium and mice is regulated by NF-κB (promotes expression) and STAT6 (required for CCL17 but not CCL22 in mice); type-2 cytokines and STAT6 activation increased CCL17 while suppressing CCL22; STAT6-knockout mice showed increased NF-κB chemokines with rapid viral clearance. Human RV challenge model, in vitro air-liquid interface primary epithelial cells, STAT6-knockout mice, in vivo RV mouse model American journal of respiratory cell and molecular biology Medium 33264064
2022 CCL17 is expressed by CCR2+ macrophages and CD11b+ conventional dendritic cells after myocardial injury; GM-CSF signaling drives CCL17 expression through cooperative activation of STAT5 and canonical NF-κB. CCL17 inhibits Treg recruitment by biased activation of CCR4: CCL17 activates only Gq signaling whereas CCL22 activates both Gq and β-arrestin (ARRB) downstream of CCR4; CCL17 competitively inhibited CCL22-stimulated ARRB signaling and Treg migration. Ccl17 deletion improved LV remodeling and systolic function in a Treg-dependent manner. Ccl17 knockout mice, flow cytometry, RNA sequencing, biochemical signaling assays (Gq vs ARRB pathway dissection), cell trafficking studies, in vivo cell depletion, multiple injury models Circulation High 35113652
2022 CCL17 activates CCR4/mTORC2 signaling in microglia after subarachnoid hemorrhage to promote M2-like polarization and neuroprotection; in vitro kinase assay confirmed mTORC2 activation; microglial-specific Rictor (mTORC2 component) knockdown via AAV abolished rCCL17 neuroprotection. CCL17 is secreted from neurons after oxyhemoglobin stimulation. In vitro kinase assay in primary microglia, intracerebroventricular AAV-mediated Rictor knockdown, in vivo rat SAH model, CCR4 inhibitor AZD2098 Stroke and vascular neurology Medium 35882433
2022 CCL17 drives pathological cardiac hypertrophy and heart failure via T cell plasticity; Ccl17-KO significantly repressed aging- and Angiotensin II-induced cardiac hypertrophy/fibrosis accompanied by altered T cell subset differentiation; therapeutic anti-CCL17 neutralizing antibody inhibited Ang II-induced cardiac remodeling. Ccl17 knockout mice, neutralizing antibody treatment, Ang II infusion model, T cell subset flow cytometry The Journal of experimental medicine Medium 35687056
2023 CCL17 drives pulmonary fibrosis by acting through CCR4 on fibroblasts to activate TGF-β/Smad signaling, promoting fibroblast activation and collagen production; CCL17 upregulated in alveolar macrophages; anti-CCL17 antibody blockade and CCR4-siRNA or CCR4 antagonist reduced BLM-induced fibrosis in mice. siRNA knockdown of CCR4, CCR4 antagonist C-021, anti-CCL17 antibody, bleomycin mouse model, Western blot (TGF-β/Smad pathway), immunofluorescence Biochemical pharmacology Medium 36870575

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. The Journal of clinical investigation 225 21633167
2006 Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. Journal of dermatological science 222 16859899
2004 Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. The Journal of allergy and clinical immunology 213 14767451
2021 Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17. Theranostics 168 33664865
2004 Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. Journal of dermatological science 156 15113590
2008 Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 142 18541724
2003 Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. Journal of the American Academy of Dermatology 126 12522366
2022 CCL17 Aggravates Myocardial Injury by Suppressing Recruitment of Regulatory T Cells. Circulation 109 35113652
2017 The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity. International journal of molecular sciences 108 29099057
2012 Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 94 23224400
2011 CCL17 promotes intestinal inflammation in mice and counteracts regulatory T cell-mediated protection from colitis. Gastroenterology 85 22057112
2011 Casuarinin suppresses TARC/CCL17 and MDC/CCL22 production via blockade of NF-κB and STAT1 activation in HaCaT cells. Biochemical and biophysical research communications 85 22227193
2004 E-selectin, thymus- and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system. Journal of immunology (Baltimore, Md. : 1950) 82 14734737
2001 The CC chemokines MDC and TARC induce platelet activation via CCR4. Thrombosis research 81 11248289
2018 CCL17 blockade as a therapy for osteoarthritis pain and disease. Arthritis research & therapy 77 29622035
2006 IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. European journal of immunology 77 16810739
2009 Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis. Respiratory research 76 19715610
2004 Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors. Annals of the rheumatic diseases 76 15331393
2001 Stem cell factor and igE-stimulated murine mast cells produce chemokines (CCL2, CCL17, CCL22) and express chemokine receptors. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 73 11339505
2010 CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis and rheumatism 70 20669282
2010 Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. Journal of hepatology 69 21129807
2009 The adenylyl cyclase-cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF-kappaB in HaCaT keratinocytes. Molecular immunology 68 19371952
2009 Suppression of thymus- and activation-regulated chemokine (TARC/CCL17) production by 1,2,3,4,6-penta-O-galloyl-beta-D-glucose via blockade of NF-kappaB and STAT1 activation in the HaCaT cells. Biochemical and biophysical research communications 67 19576177
2004 CCL22 and CCL17 in rat radiation pneumonitis and in human idiopathic pulmonary fibrosis. The European respiratory journal 65 15293604
2016 Tumor-associated macrophage or chemokine ligand CCL17 positively regulates the tumorigenesis of hepatocellular carcinoma. Medical oncology (Northwood, London, England) 63 26781124
2015 Ginsenoside Rg5:Rk1 attenuates TNF-α/IFN-γ-induced production of thymus- and activation-regulated chemokine (TARC/CCL17) and LPS-induced NO production via downregulation of NF-κB/p38 MAPK/STAT1 signaling in human keratinocytes and macrophages. In vitro cellular & developmental biology. Animal 62 26714752
2011 A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation. The Journal of investigative dermatology 60 21593768
2001 Expression of C-C chemokine TARC in human nasal mucosa and its regulation by cytokines. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 56 11737045
2005 Elevated expression of TARC (CCL17) and MDC (CCL22) in models of cigarette smoke-induced pulmonary inflammation. Biochemical and biophysical research communications 55 15993846
2021 Recombinant CCL17-dependent CCR4 activation alleviates neuroinflammation and neuronal apoptosis through the PI3K/AKT/Foxo1 signaling pathway after ICH in mice. Journal of neuroinflammation 54 33648537
2011 Kinetics and differential expression of the skin-related chemokines CCL27 and CCL17 in psoriasis, atopic dermatitis and allergic contact dermatitis. Experimental dermatology 54 21707761
2015 CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma. Cancer immunology, immunotherapy : CII 53 25754123
2007 Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17. Journal of immunology (Baltimore, Md. : 1950) 53 17641031
2006 Interleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter. BMC molecular biology 53 17134490
2023 CCL17/TARC in autoimmunity and inflammation-not just a T-cell chemokine. Immunology and cell biology 52 36975092
2006 Der p, IL-4, and TGF-beta cooperatively induce EGFR-dependent TARC expression in airway epithelium. American journal of respiratory cell and molecular biology 51 17023689
2005 Mechanism of thymus- and activation-regulated chemokine (TARC)/CCL17 production and its modulation by roxithromycin. The Journal of investigative dermatology 51 16117790
2003 Monocyte-derived dendritic cells exposed to Der p 1 allergen enhance the recruitment of Th2 cells: major involvement of the chemokines TARC/CCL17 and MDC/CCL22. European cytokine network 51 14715413
2017 MiR-155-5p positively regulates CCL17-induced colon cancer cell migration by targeting RhoA. Oncotarget 50 28146427
2018 TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17. JCI insight 49 29563337
2019 Inflammatory macrophages switch to CCL17-expressing phenotype and promote peritoneal fibrosis. The Journal of pathology 48 31579932
2018 Epigenetic and transcriptional regulation of IL4-induced CCL17 production in human monocytes and murine macrophages. The Journal of biological chemistry 48 29871928
2008 Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder. Cancer science 46 18271928
2003 Thymus and activation-regulated chemokine (TARC/CCL17) produced by mouse epidermal Langerhans cells is upregulated by TNF-alpha and IL-4 and downregulated by IFN-gamma. Cytokine 46 12967648
2020 Recombinant CCL17 Enhances Hematoma Resolution and Activation of CCR4/ERK/Nrf2/CD163 Signaling Pathway After Intracerebral Hemorrhage in Mice. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 45 32783091
2021 What does elevated TARC/CCL17 expression tell us about eosinophilic disorders? Seminars in immunopathology 43 34009399
2018 CCL17 exerts a neuroimmune modulatory function and is expressed in hippocampal neurons. Glia 42 30277599
2010 Titanium induced production of chemokines CCL17/TARC and CCL22/MDC in human osteoclasts and osteoblasts. Journal of biomedical materials research. Part A 41 19205012
2004 Thymus- and activation-regulated chemokine (TARC/CCL17) induces a Th2-dominated inflammatory reaction on intradermal injection in mice. Experimental dermatology 41 15086343
2005 T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer immunology, immunotherapy : CII 40 16267679
2003 Demonstration of TARC and CCR4 mRNA expression and distribution using in situ RT-PCR in the lesional skin of atopic dermatitis. The Journal of dermatology 40 12598706
2020 CCL17 in Inflammation and Pain. Journal of immunology (Baltimore, Md. : 1950) 39 32461237
2013 CCR4 mediates CCL17 (TARC)-induced migration of human colon cancer cells via RhoA/Rho-kinase signaling. International journal of colorectal disease 39 23649168
2013 CCL17/thymus and activation-regulated chemokine induces calcitonin gene-related peptide in human airway epithelial cells through CCR4. The Journal of allergy and clinical immunology 39 23731651
2010 Sulforaphane suppresses TARC/CCL17 and MDC/CCL22 expression through heme oxygenase-1 and NF-κB in human keratinocytes. Archives of pharmacal research 39 21116791
2010 Elevated umbilical cord serum TARC/CCL17 levels predict the development of atopic dermatitis in infancy. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 38 21054588
2018 Intratumoral IFN-α gene delivery reduces tumor-infiltrating regulatory T cells through the downregulation of tumor CCL17 expression. Cancer gene therapy 36 30420718
2020 Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. Integrative biology : quantitative biosciences from nano to macro 35 32638026
2012 Suppression of thymus- and activation-regulated chemokine (TARC/CCL17) production by 3-O-β-D-glucopyanosylspinasterol via blocking NF-κB and STAT1 signaling pathways in TNF-α and IFN-γ-induced HaCaT keratinocytes. Biochemical and biophysical research communications 35 22943853
2003 Lack of evidence for TARC/CCL17 production by normal human keratinocytes in vitro. Journal of dermatological science 35 12615362
2018 A Novel Function for 15-Lipoxygenases in Cholesterol Homeostasis and CCL17 Production in Human Macrophages. Frontiers in immunology 34 30197642
2011 Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 33 22017510
2005 Production of a monoclonal antibody to canine thymus and activation-regulated chemokine (TARC) and detection of TARC in lesional skin from dogs with atopic dermatitis. Veterinary immunology and immunopathology 33 15626464
2022 CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure. The Journal of experimental medicine 32 35687056
2008 TARC and IL-5 expression correlates with tissue eosinophilia in peripheral T-cell lymphomas. Leukemia research 32 18395252
2003 TGF-beta/Smad signaling inhibits IFN-gamma and TNF-alpha-induced TARC (CCL17) production in HaCaT cells. Journal of dermatological science 32 12615364
2002 IL-4, but not IL-13, modulates TARC (thymus and activation-regulated chemokine)/CCL17 and IP-10 (interferon-induced protein of 10kDA)/CXCL10 release by TNF-alpha and IFN-gamma in HaCaT cell line. Cytokine 31 12441140
2011 Psidium guajava extract inhibits thymus and activation-regulated chemokine (TARC/CCL17) production in human keratinocytes by inducing heme oxygenase-1 and blocking NF-κB and STAT1 activation. Environmental toxicology and pharmacology 30 21843792
2003 Production of TARC and MDC by naive T cells in asthmatic patients. Journal of clinical immunology 30 12645858
2020 Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis. Scientific reports 29 33033277
2014 HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation. Biochemical and biophysical research communications 29 24582560
2018 Loss of GRHL3 leads to TARC/CCL17-mediated keratinocyte proliferation in the epidermis. Cell death & disease 28 30341279
2022 EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22. PLoS pathogens 26 35025968
2004 TARC augments TNF-alpha-induced CTACK production in keratinocytes. Experimental dermatology 26 15335355
2004 Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. Journal of dermatological science 26 15541638
2003 A role for TARC/CCL17, a CC chemokine, in systemic lupus erythematosus. The Journal of rheumatology 26 14677179
2021 Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6. American journal of respiratory cell and molecular biology 25 33264064
2021 The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment. Cancer science 25 34449935
2016 CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. Cancer medicine 25 26758564
2007 Wogonin suppresses TARC expression induced by mite antigen via heme oxygenase 1 in human keratinocytes. Suppressive effect of wogonin on mite antigen-induced TARC expression. Journal of dermatological science 25 17317108
2001 Quantitation of chemokines (MDC, TARC) expression in mucosa from Crohn's disease and ulcerative colitis. European cytokine network 25 11566628
2022 CCL17 exerts neuroprotection through activation of CCR4/mTORC2 axis in microglia after subarachnoid haemorrhage in rats. Stroke and vascular neurology 24 35882433
2021 Skullcapflavone II Suppresses TNF-α/IFN-γ-Induced TARC, MDC, and CTSS Production in HaCaT Cells. International journal of molecular sciences 24 34208434
2018 TARC expression in the circulation and cutaneous granulomas correlates with disease severity and indicates Th2-mediated progression in patients with sarcoidosis. Allergology international : official journal of the Japanese Society of Allergology 24 29598931
2017 RNA Aptamers Recognizing Murine CCL17 Inhibit T Cell Chemotaxis and Reduce Contact Hypersensitivity In Vivo. Molecular therapy : the journal of the American Society of Gene Therapy 24 29103909
2014 CCL17 production by dendritic cells is required for NOD1-mediated exacerbation of allergic asthma. American journal of respiratory and critical care medicine 24 24661094
2014 Serum chemokine CCL17/thymus activation and regulated chemokine is correlated with coronary artery diseases. Atherosclerosis 24 25555269
2016 Cannabinoid Receptor 2 Modulates Susceptibility to Experimental Cerebral Malaria through a CCL17-dependent Mechanism. The Journal of biological chemistry 23 27474745
2014 CCL17 Induces Trophoblast Migration and Invasion by Regulating Matrix Metalloproteinase and Integrin Expression in Human First-Trimester Placenta. Reproductive sciences (Thousand Oaks, Calif.) 23 24401476
2023 CCL17 drives fibroblast activation in the progression of pulmonary fibrosis by enhancing the TGF-β/Smad signaling. Biochemical pharmacology 21 36870575
2018 CCL17-CCR4 axis promotes metastasis via ERK/MMP13 pathway in bladder cancer. Journal of cellular biochemistry 21 30230587
2014 Expression of thymus and activation-regulated chemokine (TARC) by human dermal cells, but not epidermal keratinocytes. Journal of dermatological science 21 25219597
2018 CCL17/TARC and CCR4 expression in Merkel cell carcinoma. Oncotarget 20 30140381
2016 Biomarker assessment in chronic rhinitis and chronic rhinosinusitis: Endothelin-1, TARC/CCL17, neopterin, and α-defensins. Allergy and asthma proceedings 20 26831845
2007 Expression of chemokine receptor CCR4 and its ligands (CCL17 and CCL22) in murine contact hypersensitivity. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20 18052724
2020 HBV promotes the recruitment of IL-17 secreting T cells via chemokines CCL22 and CCL17. Liver international : official journal of the International Association for the Study of the Liver 19 32187823
2016 Inhibitory effect of a histamine 4 receptor antagonist on CCL17 and CCL22 production by monocyte-derived Langerhans cells in patients with atopic dermatitis. The Journal of dermatology 19 26892271
2021 Biology and Clinical Applicability of Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma. Cancers 18 33672548
2019 Serum miR-125a-5p and CCL17 Upregulated in Chronic Spontaneous Urticaria and Correlated with Treatment Response. Acta dermato-venereologica 18 30809682
2005 Exposure to TARC alters beta2-adrenergic receptor signaling in human peripheral blood T lymphocytes. American journal of physiology. Lung cellular and molecular physiology 18 15749741

Missed literature

Know a paper Affinage missed for CCL17? Flag it for the maintainers and the community.

No submissions yet.